Spruce Biosciences’ (SPRB) “Sell (D-)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of Spruce Biosciences (NASDAQ:SPRB) in a research note published on Tuesday,Weiss Ratings reports.

Spruce Biosciences Stock Performance

NASDAQ SPRB opened at $176.91 on Tuesday. The stock’s fifty day moving average is $30.67 and its two-hundred day moving average is $16.65. The firm has a market capitalization of $99.07 million, a P/E ratio of -2.05 and a beta of 2.47. Spruce Biosciences has a fifty-two week low of $4.28 and a fifty-two week high of $240.00.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.